TapImmune (NASDAQ:MRKR) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, ValuEngine reports.
Other research analysts have also issued research reports about the company. Zacks Investment Research lowered TapImmune from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. Roth Capital initiated coverage on TapImmune in a research note on Thursday, May 30th. They set a “buy” rating and a $10.00 price target on the stock. Oppenheimer initiated coverage on TapImmune in a research note on Wednesday, July 3rd. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of TapImmune in a research note on Sunday, July 21st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. TapImmune has a consensus rating of “Buy” and an average price target of $10.21.
Shares of TapImmune stock traded down $0.04 during trading hours on Thursday, reaching $4.26. 447,065 shares of the company’s stock were exchanged, compared to its average volume of 896,693. TapImmune has a 52-week low of $4.18 and a 52-week high of $10.60. The company has a market capitalization of $209.68 million, a price-to-earnings ratio of -2.55 and a beta of 0.22. The company’s fifty day moving average is $7.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.73 and a quick ratio of 19.73.
TapImmune (NASDAQ:MRKR) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. As a group, equities analysts forecast that TapImmune will post -0.51 EPS for the current year.
A hedge fund recently raised its stake in TapImmune stock. Riggs Asset Managment Co. Inc. increased its position in TapImmune Inc. (NASDAQ:MRKR) by 68.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,919 shares of the company’s stock after buying an additional 18,650 shares during the quarter. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 33.59% of the company’s stock.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Featured Story: Lock-Up Period Expiration
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.